Measurement of response rate and time to disease progression in patients with chronic lymphocytic leukemia using fludarabine and the anti-CD20 antibody rituximab (IDEC-C2B8).

Trial Profile

Measurement of response rate and time to disease progression in patients with chronic lymphocytic leukemia using fludarabine and the anti-CD20 antibody rituximab (IDEC-C2B8).

Completed
Phase of Trial: Phase II

Latest Information Update: 23 Feb 2010

At a glance

  • Drugs Fludarabine; Rituximab
  • Indications Chronic lymphocytic leukaemia
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Roche
  • Most Recent Events

    • 23 Feb 2010 Status changed from active, no longer recruiting to completed as reported by Roche record.
    • 09 Jun 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top